Respiratory system drugs – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:22 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg Respiratory system drugs – CRI Report https://www.cri-report.com 32 32 Investigation Report on Chinese Salmeterol/Ticasone Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinese-salmeterol-ticasone-market-2021-2025/ Fri, 21 May 2021 06:26:26 +0000 https://www.cri-report.com/?post_type=product&p=11421 Description Salmeterol/Ticasone is a compound medication used in regular treatment of asthma and chronic obstructive pulmonary disease (COPD). Its original drug was developed by GlaxoSmithKline. In 2001, Salmeterol Ticasone powder inhalation was approved to enter the Chinese market, and its indication was chronic obstructive pulmonary disease (COPD), and its trade name was SERETIDE; a new indication for asthma was added in China in 2010. SERETIDE powder inhalation has been covered in the category B medical insurance catalogs of 31 provinces, and by 2020 the manufacturers of Salmeterol/Ticasone in China is…

The post Investigation Report on Chinese Salmeterol/Ticasone Market 2021-2025 first appeared on CRI Report.

]]> Description
Salmeterol/Ticasone is a compound medication used in regular treatment of asthma and chronic obstructive pulmonary disease (COPD). Its original drug was developed by GlaxoSmithKline. In 2001, Salmeterol Ticasone powder inhalation was approved to enter the Chinese market, and its indication was chronic obstructive pulmonary disease (COPD), and its trade name was SERETIDE; a new indication for asthma was added in China in 2010. SERETIDE powder inhalation has been covered in the category B medical insurance catalogs of 31 provinces, and by 2020 the manufacturers of Salmeterol/Ticasone in China is Glaxo Wellcome(formerly the welcome Foundation) and GlaxoSmithKline(France).

According to CRI’s market research, the sales of Salmeterol/Ticasone have had an increasing trend in the Chinese market from 2016 to 2019.The sales revenue in 2020 was approximately CNY296.77million. However, the sales of Salmeterol/Ticasone in 2020 decreased by 21.59% compared with that in 2019 due to the COVID-19 epidemic. The CAGR for Salmeterol/Ticasone is approximately -3.82% from 2016 to 2020.

According to CRI analysis, from 2021 to 2025, the sales of Salmeterol/Ticasone in China will have a recovery growth with the improvement of the epidemic situation and normal operation of overall diagnosis and treatment in hospitals. After the patent for Salmeterol/Ticasone expired, more biosimilar drugs will appear in the market. In China, Respirent Pharmaceuticals Co. Ltd has already submitted an application for Salmeterol/Ticasone in 2021. Therefore, in the next few years, the market share for Glaxo Wellcome (formerly the wellcome Foundation) and GlaxoSmithKline (France) will gradually shrink. At the same time, with the launch of biosimilar drugs, the price will be further reduced. The price adjustment will reduce the burden on patients, thereby increasing the use and sales of Salmeterol/Ticasone.

Topics Covered:
-The impact of COVID-19 on China’s Salmeterol/Ticasone market
– Sales value of China’s Salmeterol/Ticasone 2016-2020
– Competitive landscape of China’s Salmeterol/Ticasone market
– Prices of Salmeterol/Ticasone in China
– Prices of Salmeterol/Ticasone in China by regions and manufacturers
– Analysis on factors affecting the development of China’s Salmeterol/Ticasone market
– Prospect of China’s Salmeterol/Ticasone market from 2021 to 2025

The post Investigation Report on Chinese Salmeterol/Ticasone Market 2021-2025 first appeared on CRI Report.

]]>